– Proof-of-Concept Trial Confirms ZT-01's Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes – – First-in-Class ZT-01 ...
 Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01.
TORONTO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc. (“Zucara” or the “Company”), a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has expanded the development of ZT-01, a somatostatin receptor 2 antagonist (“SSTR2a”), to Type 2 Diabetes (“T2D”).